A personalized therapeutic vaccine based on mRNA technology has been shown to reduce the risk of recurrence in melanoma by 42%, combined with immunotherapy, according to the results of the phase 3 INTerpath-001 study presented at the Congress of the European Society for Medical Oncology. #VaccinoPersonalizzato #Melanoma #mRna (translated)
www.ansa.it
Melanoma, primo vaccino 'su misura' riduce il rischio di recidiva del 42%
